Pancreatic cancer today

Hepato-Gastroenterology

Volumn 51, Issue 57, 2004, Pages 862-868

  Safioleas, Michael C ^a   Moulakakis, Konstantinos G ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Chemotherapy; Familial pancreatic cancer; Pancreatic cancer; Radiotherapy; Surgery; TNM staging

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN;

ADJUVANT THERAPY; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMMUNOTHERAPY; MAGNETIC RESONANCE ANGIOGRAPHY; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; TUMOR GROWTH;

COMBINED MODALITY THERAPY; HUMANS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 2342643452     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Sohn TA, Yeo CJ: The molecular genetics of pancreatic ductal carcinoma: a review. Surg Oncol 2000; 9(3):95-101. (Review)
2. Wanebo HJ, Vezeridis MP: Pancreatic carcinoma in perspective. A continuing challenge. Cancer 1996; 78(3 Suppl):580-591. (Review)
3. Goggins M, Canto M, Hruban R: Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol 2000; 74(4):243-248. (Review)
4. El Kamar FG, Grossbard ML, Kozuch PS: Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. Oncologist 2003; 8:18-34.
5. Ihse I, Anderson R, Axelson J, Hansson L: Surgical treatment for patients with advanced pancreatic cancer J Hepatobiliary Pancreat Surg 1998; 5(2):133-137.
6. Wolff RA, Abbruzzese JL, Evans DB: Neoplasms of the exocrine pancreas. In: Bast RC Jr., Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III (Eds.). Cancer Medicine. Edition 5. London: BC Decker Inc., 2000; pp. 1438-1459.
7. Redlich PN, Ahrendt SA, Pitt HA: Tumors of the pancreas, gallbladder, and bile ducts. In: Lenhard RE Jr., Osteen RT, Gansler T (Eds.). The American Cancer Society's, Clinical oncology. Atlanta, Georgia: pp. 373-395.
8. Mortality tables. CDC, National Center for Health Statistics; www.cdc.gov.nehs.
9. Gold EB, Goldin SB: Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 1998; 7(1):67-91. (Review)
10. Silverman DT: Risk factors for pancreatic cancer: a case-control study based on direct interviews. Teratog Carcinog Mutagen 2001; 21(1):7-25.
11. Evans DB, Abbruzzese JL, Rich TA: Cancer of the pancreas. In: DeVita VT Jr, Hellman S, Rosenberg SA (Eds.). Cancer: Principles and Practice of Oncology (5th Edition). Philadelphia: Lippincott-Raven, 1997; pp. 1054-1087.
12. Ghadirian P, Lynch HT, Krewski D: Epidemiology of pancreatic cancer an overview. Cancer Detect Prev 2003; 27(2):87-93.
13. American Cancer Society: Atlas of clinical oncology. In: Cameron JL (Ed.). Pancreatic cancer. London: BC Decker Inc., 2001; pp. 13-14.
14. Schneider G, Schmid RM: Genetic alterations in pancreatic carcinoma. Mol Cancer 2003; 2(1):15.
15. International Hepato-Pancreato-Biliary Association, IHPBA: Conference report: Molecular biology in pancreatic cancer. p.283 Tokyo, April 25-29, 2002. J Hepatobiliary Pancreat Surg 2002; 9(3):281-303.
16. Yuan S, Rosenberg L, Paraskevas S, Agapitos D, Doguid, WP: Transdifferentiation of human islets to pancreatic ductal cells in collagen matrix culture. Differentiation 1996; 61:67.
17. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53(4):549-554.
18. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL: KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988; 16(16):7773-7782.
19. Masson P, Andren-Sandberg A: Crude isolation of DNA from unselected human pancreatic tissue and amplification by the polymerase chain reaction of Ki-ras oncogene to detect point mutations in pancreatic cancer. Acta Oncol 1992; 31(4):421-424.
20. Sobin LH, Wittekind CH (Eds.): UICC TNM classification of malignant tumours. 5th Edition. New York: Wiley-Liss, 1997.
21. Pellegata NS, Losekoot M, Fodde R, Pugliese V, Saccomanno S, Renault B, Bernini LF, Ranzani GN: Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer. Anticancer Res 1992; 12(5):1731-1735.
22. Traverso LW: What are the problems associated with the surgical treatment of patients with pancreatic cancer. J Hepatobiliary Pancreat Surg 1998; 5(2):138-142.
23. Tsunoda T, Yamamoto Y, Kimoto M, Imai H, Iwamoto S, Kawasaki S, Kawashima K, Tadaoka Y, Majima T, Onuma E, Iki K, Kubozoe T, Eto T: Staging and treatment for patients with pancreatic cancer. How small is an early pancreatic cancer? J Hepatobiliary Pancreat Surg 1998; 5(2):128-132.
24. Yamamoto M: A general view of pancreatic cancer in Japan and a proposal for a more practical staging system. Int J Clin Oncol 1999; 4:267-272.
25. Pancreas (ICD-0 157.0-3). In: Hermanek P, Sobin LH (Eds.). UICC TNM Classification of malignant tumours. 4th Edition. Berlin Heidelberg New York Springer, 1987; pp. 65-66.
26. Ferrucci JT: MRI and MRCP in pancreatobiliary malignancy. Ann Oncol 1999; 10:18-19.
27. DiMagno EP, Reber HA, Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999; 117:1464-1484.
28. Barkin J, Goldstein J: Diagnostic approach to pancreatic cancer. In: Barkin J, Lankisch PG (Eds.). Pancreas update. Philadelphia: WB Saunders, 1999; pp. 709-722.
29. Rivera JA, Fernandez-del Castillo C, Warshaw AL: The preoperative staging of pancreatic adenocarcinoma In: Cameron JL, (Ed.). Advances in surgery. Boston: Mosby-Year Book; 1996; pp. 97-122.
30. Ji BT, Silverman DT, Stewart PA, Blair A, Swanson GM, Baris D, Greenberg RS, Hayes RB, Brown LM, Lillemoe KD, Schoenberg JB, Pottern LM, Schwartz AG, Hoover RN: Occupational exposure to pesticides and pancreatic cancer. Am J Ind Med 2001; 39(1):92-99. Erratum in: Am J Ind Med 2001; 40(2):225-226.
31. Ichikawa T, Haradome H, Hachiya J, et al: Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT vs. dynamic MR imaging. Radiology 1997; 202:655-662.
32. Gabata T, Matsui O, Kadoya M, et al: Small pancreatic adenocarcinomas: efficacy of MR imaging with fat suppression and gadolinium enhancement. Radiology 1994; 193:683-688.
33. Zimny M, Buell U: 18FDG-positron emission tomography in pancreatic cancer. Ann Oncol 1999; 10(Suppl 4):28-32.
34. Price P: Changes in 18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got? Br J Cancer 2000; 83:281-283.
35. Meyer S, Bittinger F, Keth A, Von Mach MA, Kann PH: [Endosonographically controlled transluminal fine needle aspiration biopsy: diagnostic quality by cytologic and histopathologic classification]. Dtsch Med Wochenschr 2003; 128(30):1585-1591. (In German)
36. Yamaguchi K, Shimizu S, Yokohata K, Noshiro H, Chijiiwa K, Tanaka M: Pancreatic carcinoma: reappraisal of surgical experiences in one Japanese university hospital. Hepatogastroenterology 1999; 46(30):3257-3262.
37. Nitecki SS, Sarr MG, Colby TV, et al: Long term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221:59-66.
38. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, El-Naggar AK, Fenoglio CJ, Lee JE, Evans DB: Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996; 223(2):154-112.
39. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP: Treatment and survival in 13560 patients with pancreatic cancer and incidence of the disease in the West Midlands: an epidemiological study. Br J Surg 1995; 82(1):111-115.
40. Engelken FGF, Bettschart V, Rahman MQ, Parks RW, Garden OJ: Prognostic factors in the palliation of pancreatic cancer. EJSO 2003; 29:368-373.
41. McKenna S, Eatock M: The medical management of pancreatic cancer: a review. Oncologist 2003; 8(2):149-160.
42. Glimelius B: Chemotherapy in the treatment of cancer of the pancreas. J Hepatobiliary Pancreat Surg 1998; 5(3):235-241. (Review)
43. Sporn JR: Practical recommendations for the management of adenocarcinoma of the pancreas. Drugs 1999; 57(1):69-79. (Review)
44. Van Riel JM, van Groeningen CJ, Pinedo HM, Giaccone G: Current chemotherapeutic possibilities in pancreaticobiliary cancer. Ann Oncol 1999;10(Suppl 4):157-161. (Review)
45. Rosemurgy AS, Serafini FM: New directions in systemic therapy of pancreatic cancer. Cancer Control 2000; 7(5):437-451. (Review)
46. Rosenberg L: Pancreatic cancer: a review of emerging therapies. Drugs 2000; 59(5):1071-1089. (Review)
47. Permert J, Hafstrom L, Nygren P, Glimelius B, SBU-group: Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol 2001; 40(2-3):361-370. (Review)
48. Kozuch P, Petryk M, Evans A, Bruckner HW: Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review. Surg Clin North Am 2001; 81(3):683-690. (Review)
49. Oettle H, Arnold D, Hempel C, Riess H: The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 2000; 11(10):771-786. (Review)
50. Heinemann V: Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001; 60(1):8-18. (Review)
51. Ahlgren JD: Chemotherapy for pancreatic carcinoma. Cancer 1996; 78(3 Suppl):654-663. (Review)
52. Magnin V, Moutardier V, Giovannini MH, Lelong B, Giovannini M, Viret F, Monges G, Bardou VJ, Alzieu C, Delpero JR: Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys 2003; 55(5):1300-1304.
53. Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120(8):899-903. Erratum in: Arch Surg 1986; 121(9):1045.
54. Fung MC, Sakata T: What's new in pancreatic cancer treatment? J Hepatobiliary Pancreat Surg 2002; 9:61-75.
55. Heinemann V: Gemcitabine in the treatment of advanced pancreatic cancer a comparative analysis of randomized trials. Semin Oncol 2002; 29(6 Suppl 20):9-16. (Review)
56. Oettle H, Arning M, Pelzer U, Arnold D, Stroszczynski C, Langrehr J, Reitzig P, Kindler M, Herrenberger J, Musch R, Korsten EW, Huhn D, Riess H: A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol 2000; 11(10):1267-1272.
57. Heinemann V: Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001; 60(1):8-18. (Review)
58. Abrams RA, Isacoff WH: Chemotherapy and Radiation Therapy in the adjuvant management of pancreatic cancer. In: Cameron JL (Ed.). American Cancer Society, atlas of clinical oncology. Pancreatic cancer. London: BC Decker Inc., 2001; pp. 154-170.
59. Heinemann V: Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol 2002; 29(1 Suppl 3):25-35. (Review)
60. Haller DG: Future directions in the treatment of pancreatic cancer. Semin Oncol 2002; 29(6 Suppl 20):31-39.
61. El-Rayes BF, Shields AF, Vaitkevicius V, Philip PA: Developments in the systemic therapy of pancreatic cancer. Cancer Invest 2003; 21(1):73-86.
62. EL-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA: Phase II study of gemcitabine, Cisplatin and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 2003; 21(15):2920-2925.
63. Dobelbower RR, Battle JA, Konski AA: External beam radiation therapy for pancreatic cancer. In: Beger HG, et al. (Eds.). The Pancreas. Vol. 2. Osney Mead, Oxford: Blackwell Science, 1998; p. 1071.
64. Beger HG, Poch B, Schwarz M, Gansauge F: Pancreatic cancer. The relative importance of neoadjuvant therapy. Chirurg 2003; 74(3):202-207.
65. Tsai JY, Iannitti DA, Safran H: Combined modality therapy for pancreatic cancer. Semin Oncol 2003; 30(4 Suppl 9):71-79.
66. Lygidakis NJ, Sgourakis G, Georgia D, Vlachos L, Raptis S: Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg 2002; 236(6):806-813.
67. Lygidakis NJ, Vlachos L, Raptis S, Sgourakis G, Mourikis D, Kehagias D: Consecutive re-explorations for final resection of initially unresectable pancreatic head carcinoma. Hepatogastroenterology 1999; 46(28):2229-2239.
68. Lygidakis NJ, Spentzouris N, Theodoracopoulos M, Dedemadi G, Gemos K, Kyriakou A: Pancreatic resection for pancreatic carcinoma combined with neo- and adjuvant locoregional targeting immuno-chemotherapy - a prospective randomized study. Hepatogastroenterology 1998; 45(20):396-403.
69. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59:2006-2020.
70. Demeure MD, Doflek KM, Komorowski RA, et al: Molecular metastases in stage I pancreatic cancer: improved survival with adjuvant chemoradiation. Surgery 1998; 124:663-669.
71. Evans DB, Rich TA, Byrd DR, et al: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127:1335-1339.